MindWalk (NASDAQ:HYFT) Announces Quarterly Earnings Results

MindWalk (NASDAQ:HYFT) announced its quarterly earnings data on Monday. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04), Zacks reports. The firm had revenue of $2.73 million during the quarter. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%.

Here are the key takeaways from MindWalk’s conference call:

• Positive Sentiment: First-quarter revenue rose 21% year over year to CAD 3.8 million, marking five consecutive quarters of annual growth, while gross margin expanded to 59% from 48%.
• Neutral Sentiment: MindWalk is negotiating ReefIQ enterprise deployments with multiple large pharmaceutical companies, but no contracts or values have been announced; management said enterprise adoption will likely produce lumpy, milestone-based revenue before transitioning to recurring revenue.
• Positive Sentiment: Approximately 80% of the company’s current commercial funnel by value is structured as platform partnerships that may include milestone and royalty economics, rather than fee-for-service work, potentially increasing long-term asset-related upside.
• Negative Sentiment: The net loss from continuing operations widened to CAD 6.1 million from CAD 4.1 million, driven partly by higher commercial investment; sales and marketing expense increased to CAD 3.2 million from CAD 1.3 million, while cash declined to CAD 7.6 million from CAD 11.3 million at quarter-end.
• Positive Sentiment: MindWalk secured a commitment for a US$30 million unsecured revolving credit facility at a fixed 7% rate, providing additional liquidity without immediate equity dilution, although the company expects to draw funds only as needed.

MindWalk Stock Performance

NASDAQ:HYFT opened at $1.33 on Tuesday. The stock’s 50-day moving average is $1.37 and its 200-day moving average is $1.36. MindWalk has a 1-year low of $0.99 and a 1-year high of $2.99. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26. The stock has a market cap of $62.13 million, a P/E ratio of -6.05 and a beta of 0.82.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HYFT shares. Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Zacks Research lowered MindWalk from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $5.00.

More MindWalk News

Here are the key news stories impacting MindWalk this week:

• Positive Sentiment: Revenue and margins improved: Fiscal Q1 2027 revenue rose 21.3% year over year to $3.8 million, while gross profit increased 47.1% to $2.2 million. Gross margin expanded substantially to 58.6% from 48.3%, supporting the company’s shift toward higher-margin, recurring platform revenue. MindWalk Reports 21% Revenue Growth and Gross Margin Expansion
• Positive Sentiment: ReefIQ commercial launch: The launch of ReefIQ™ gives MindWalk a new data-platform product and could improve the predictability of future revenue if adoption develops as expected. MindWalk fiscal first-quarter results
• Positive Sentiment: Non-dilutive funding commitment: MindWalk secured access to a senior unsecured revolving credit facility of up to $30 million at a fixed 7% interest rate. Funds can support biologics programs, expansion and working capital without warrants, equity conversion features or immediate shareholder dilution. MindWalk $30 million credit facility
• Neutral Sentiment: Analyst stance remains cautious: Analysts have issued a consensus “Hold” recommendation, indicating limited conviction in near-term upside despite the company’s growth initiatives. MindWalk consensus Hold recommendation
• Negative Sentiment: Earnings miss: MindWalk reported a fiscal-quarter loss of $0.09 per share, wider than the $0.05 consensus loss and the $0.07 loss recorded a year earlier. The company also missed revenue estimates, while profitability remains pressured. MindWalk Q1 loss and revenue estimates

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.